Physician profile
Christopher W Wulff
NPI 1760418172
$4,776.70
in general payments reported to CMS, 2019-2025
31 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $121 · 2021: $45.72 · 2022: $17.45 · 2023: $1,255 · 2024: $1,297 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,107.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,538.20 | 2019-2024 | Gallant, Amplatzer Amulet |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $596.27 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $346.10 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $294.70 | 2023-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $215.63 | 2023-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.85 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $164.76 | 2021-2024 | Wainua, Farxiga |
| Janssen Pharmaceuticals, INC | $161.56 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $142.94 | 2023-2025 | Verquvo |
| Amgen INC. | $125.25 | 2023-2024 | Repatha |
| Heartflow, INC. | $120.92 | 2020 | |
| Boston Scientific Corporation | $98.17 | 2021-2025 | Bodyguardian, Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $93.89 | 2023-2025 | |
| Edwards Lifesciences Corporation | $78.96 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Alnylam Pharmaceuticals INC. | $75.35 | 2024-2025 | Amvuttra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $66.82 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $63.65 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $49.37 | 2024 | |
| Pfizer INC. | $40.84 | 2023-2025 | |
| Biotronik INC. | $40.78 | 2023 | Edora 8 Dr-T, Biomonitor |
| Scpharmaceuticals INC. | $37.84 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $34.72 | 2023 | Arcalyst |
| Abiomed | $34.36 | 2019-2024 | Impella |
| Daiichi Sankyo INC. | $24.27 | 2023 | Injectafer |
| Bridgebio Pharma, INC. | $23.57 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $22.15 | 2024 | Evkeeza |
| Cordis US Corp. | $20.39 | 2025 | Mynx Control Venous |
| Vifor Pharma, INC. | $19.61 | 2019 | |
| Biogen, INC. | $16.42 | 2024 | Skyclarys |
| Sanofi-Aventis U.S. LLC | $16.00 | 2023 | |
| Medtronic Vascular, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wulff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.